|
業務類別
|
Biotechnology |
|
業務概覽
|
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The companyis currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland. |
| 公司地址
| 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9 |
| 電話號碼
| +1 877 361-4003 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.helus.com |
| 員工數量
| 50 |
| Mr. Aaron Bartlone |
Chief Operation Officer |
-- |
01/07/2025 |
| Mr. Paul Glavine |
Director and Chief Growth Officer |
加元 724.55K |
01/07/2025 |
| Mr. Greg Cavers |
Chief Financial Officer |
加元 503.16K |
01/07/2025 |
| Mr. Gabriel Fahel |
Chief Legal Officer and Corporate Secretary |
美元 528.32K |
01/07/2025 |
| Mr. George Tziras |
Director and Chief Business Officer |
-- |
01/07/2025 |
| Mr. Eric So |
Director, President and Interim Chief Executive Officer |
加元 724.55K |
02/09/2025 |
|
|
| Mr. Mark Lawson |
Independent Director |
01/07/2025 |
| Ms. Theresa Firestone |
Lead Independent Director |
01/07/2025 |
| Mr. Grant Froese |
Independent Director |
01/07/2025 |
| Mr. Paul Glavine |
Director and Chief Growth Officer |
01/07/2025 |
| Dr. Eric Hoskins |
Independent Director |
01/07/2025 |
| Mr. George Tziras |
Director and Chief Business Officer |
01/07/2025 |
| Mr. Eric So |
Director, President and Interim Chief Executive Officer |
02/09/2025 |
|
|
|
|
